The UK launches its first National Centre for Neurotechnology and Neurorestoration in Newcastle to advance cutting-edge treatments and clinical trials for people living with neurological conditions.
The UK’s Horizon trial will test a vaccine against the Epstein-Barr virus (EBV), linked to multiple sclerosis, aiming to train the immune system and explore a potential new treatment for MS.
Researchers at the University of Glasgow have developed the first bioengineered human bone-marrow model to test CAR T-cell therapies for acute myeloid leukaemia, offering a more accurate, non-animal testing platform.
The University of Oxford is part of a £15.9 million UK-wide programme to develop human tumour tissue models, improving cancer research, accelerating drug discovery and reducing reliance on animal testing.
UK regulators use AI and process reforms to reduce clinical trial approvals from 91 to 41 days, speeding up patient access to new medicines and treatments.
The University of Oxford has launched a £118M AI vaccine research programme, CoI-AI, with the Ellison Institute, aiming to combat antibiotic resistance through human challenge trials.
Researchers using patient-derived stem cells reveal a rare ALS mutation triggers a chronic stress response in motor neurons, blocking it reverses damage in lab models, paving the way for new treatment strategies.
UCL and UCLH launch the Win‑Glio trial led by Dr Paul Mulholland, offering ipilimumab immunotherapy to newly diagnosed glioblastoma patients ahead of standard treatment.
The University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss, offering hope for restoring hearing function.
The government has unveiled a transformative initiative that will empower millions of NHS patients to find and join clinical trials via the NIHR’s “Be Part of Research” portal within the NHS App.
